For patients 6 years and older with ADHD
Personalized Dosing with Quillivant XR


Start with a low dose and titrate slowly to balance efficacy and side effects, which may provide an option for concerned parents

After reconstitution with water by the pharmacist: 5 mL of Quillivant XR equals 25 mg methylphenidate HCl.
Quillivant XR is taken once daily in the morning, with or without food

- Uses innovative LiquiXR® technology
- Liquid formulation available in 4 volume sizes
- With the calibrated oral dosing dispenser, the dose may be adjusted to meet the individual treatment needs of the patient
— Because Quillivant XR (methylphenidate HCl) can be titrated in small increments, you can work with your patients to determine the right dose
Patient assessment
- Prior to treatment, assess for the presence of cardiac disease (ie, perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) and risk for abuse
- After prescribing, maintain careful prescription records, educate patients about abuse, and monitor for signs of abuse and overdose
- Periodically reevaluate the need for Quillivant XR use
- If paradoxical aggravation of symptoms or other adverse reactions occur, reduce dosage or discontinue the drug, if necessary
- Quillivant XR should be periodically discontinued to assess the child’s condition. If improvement is not observed after appropriate dosage adjustment over a 1-month period, the drug should be discontinued




Quillivant XR Prescribing Guide


Formulation and administration
- Quillivant XR must be reconstituted with water by a pharmacist
- After reconstitution, the pharmacist must fully insert the bottle adapter into the neck of the bottle
- Before administering each dose, instruct the patient/caregiver to vigorously shake the bottle of Quillivant XR for at least 10 seconds to prepare suspension
Important reminders for pharmacists
- Quillivant XR is supplied as a powder for oral suspension which must be reconstituted with water prior to dispensing
- After adding the specified amount of water to the bottle, be sure to fully insert bottle adapter into neck of bottle
- Replace bottle cap. Shake with vigorous back and forth motion for at least 10 seconds to prepare suspension before dispensing prescription
- See section 2.6 in Full Prescribing Information for additional details on reconstitution
Formulation and administration
- Quillivant XR must be reconstituted with water by a pharmacist
- After reconstitution, the pharmacist must fully insert the bottle adapter into the neck of the bottle
- Before administering each dose, instruct the patient/caregiver to vigorously shake the bottle of Quillivant XR for at least 10 seconds to prepare suspension
Important reminders for pharmacists
- Quillivant XR is supplied as a powder for oral suspension which must be reconstituted with water prior to dispensing
- After adding the specified amount of water to the bottle, be sure to fully insert bottle adapter into neck of bottle
- Replace bottle cap. Shake with vigorous back and forth motion for at least 10 seconds to prepare suspension before dispensing prescription
- See section 2.6 in Full Prescribing Information for additional details on reconstitution
If switching from other methylphenidate products to Quillivant XR:
- Discontinue that treatment and titrate with Quillivant XR using the above titration schedule
- Do not substitute for other methylphenidate products on a milligram-per-milligram basis because of different methylphenidate base compositions and differing pharmacokinetic profiles
Writing a prescription for Quillivant XR
Example prescription

When prescribing multiple bottle volumes of Quillivant XR with different NDCs when 1 bottle could be used to fill the prescription, it is important to remember:
- This may result in additional out-of-pocket or for your patients
- Insurance may cover a prescription for multiple bottle volumes within one 30-day time frame; however, this may require prior authorization or a call to your patient's insurance company
CNS, central nervous system; NDC, National Drug Code; PO, by mouth.
References: 1. Wigal SB, Childress AC, Belden HW, Berry SA. J Child Adolesc Psychopharmacol. 2013;23(1):3-10.